Marksans Pharma Limited — Financials & Forensics
Sector: Healthcare · NSE: MARKSANS · BSE: 524404 · ISIN: INE750C01026
01 Oct 2026
Add MARKSANS to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹1,491 Cr | ₹1,852 Cr | ₹2,177 Cr | ₹262 Cr | ₹2,951 Cr |
| EBITDA | ₹259 Cr | ₹339 Cr | ₹459 Cr | ₹53 Cr | ₹601 Cr |
| EBITDA margin | 17.4% | 18.3% | 21.1% | 20.2% | 20.4% |
| Profit after tax | ₹187 Cr | ₹265 Cr | ₹315 Cr | ₹38 Cr | ₹420 Cr |
Deeper analysis
Recent filings by Marksans Pharma Limited
-
Press Release for Financial Results Q1 FY 27
12 Aug 2026 · Financial Results
-
Investor Presentation Q1 FY 27
12 Aug 2026 · Financial Results
-
The Board in its meeting held on 12 August 2026 approved the Unaudited Financial Results (Consolidat
12 Aug 2026 · Financial Results
Never miss a filing again
About Marksans Pharma Limited on Indian Stock Alerts
Indian Stock Alerts tracks Marksans Pharma Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.